Results 241 to 250 of about 108,143 (259)

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

New England Journal of Medicine, 2022
Michael Dickinson, Carmelo Carlo-Stella, Cyrus Khan   +2 more
exaly  

Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial

Cancer Cell, 2023
Di Fu, Hong-Mei Yi, Peng-Peng Xu
exaly  

Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma

Ca-A Cancer Journal for Clinicians, 2010
Christopher R Flowers, Rajni Sinha, Julie M Vose   +2 more
exaly  

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

Journal of Experimental Medicine, 2003
Karen Leroy, Philippe Gaulard, Randy D Gascoyne   +2 more
exaly  

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

New England Journal of Medicine, 2019
Stephen J Schuster, Michael R Bishop, Constantine S Tam   +2 more
exaly  

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

New England Journal of Medicine, 2002
Bertrand Coiffier, Josette Briere, Raoul Herbrecht   +2 more
exaly  

Diffuse large B-cell lymphoma—treatment approaches in the molecular era

Nature Reviews Clinical Oncology, 2013
Mark Roschewski, Louis M Staudt, Wyndham H Wilson   +2 more
exaly  

Diffuse large B-cell lymphoma variants: an update

Pathology, 2020
Narittee Sukswai, Kirill A Lyapichev, Joseph D Khoury   +2 more
exaly  

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

New England Journal of Medicine, 2002
George Wright, Wing C Chan, Joseph M Connors   +2 more
exaly  

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

New England Journal of Medicine, 2018
Roland Schmitz, George Wright, Calvin A Johnson   +2 more
exaly